Arthur Van Leerberghe | Executive Director, Development Business Operations and Site Head
Mirum Pharmaceuticals, Inc.

Arthur Van Leerberghe, Executive Director, Development Business Operations and Site Head, Mirum Pharmaceuticals, Inc.

Arthur Van Leerberghe is a senior clinical operations leader with over 20 years of experience in the life sciences industry. He has supported drug development programs across all clinical phases, through regulatory approval and label extensions, with a strong focus on rare and ultra-rare diseases. Arthur brings deep expertise in clinical program management, operational transformation, and change management. He currently serves as Executive Director of Development Business Operations at Mirum Pharmaceuticals, following senior leadership roles across the U.S., Europe, and Switzerland.

Appearances:



Day 2 - World Orphan Drug Congress USA 2026 @ 12:00

Continuity by Design: A Site‑ and Patient‑Centric Approach to Trial Consolidation

In rare disease development, evolving development plans can leave sponsors managing multiple active trials with overlapping sites, investigators, and fragmented governance. In this case study, Mirum describes how it consolidated four ongoing studies across two indications into a single, unified trial. Developed in close collaboration with regulators, the approach was grounded in maintaining continuity of care through a site- and patient-centric model, while enabling a more streamlined and adaptable development pathway.

The discussion will highlight the governance and operational principles that supported consolidation—improving oversight and reporting efficiency—while delivering measurable resource and budget benefits and preserving access to treatment for patients, up until commercial launch.

Key takeaways

-Decision criteria and sequencing for consolidating active trials into a single-study approach

-Governance practices that simplify oversight and improve execution

-How protocol design can reduce friction for sites and strengthen patient centricity

-Operational lessons learned and practical considerations for teams navigating trial consolidation

Session led by: Premier Research
last published: 29/Apr/26 10:45 GMT

back to speakers

Get Involved At World Orphan Drug Congress USA

 

Connect with us

 
 
 

 

To Sponsor Or Exhibit

 
 

Jack Rendell
jack.rendell@terrapinn.com
t/ +44 07577689029

 

 

 

To Speak

 
 

Abdu Kauroo
abdu.kauroo@terrapinn.com
 

 

 

 

Marketing & Press

 
 

Jasper Cameron
jasper.cameron@terrapinn.com